Sugi Predict

Sugi Predict / Compounds / SCHEMBL21570108

SCHEMBL21570108

SCHEMBL21570108

O=C(O)c1cc2n(c1)CCOC2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.42
▸ KMO O15229 2/20 0.41
▸ PIK3CA P42336 3/20 0.39
▸ KDM5A P29375 1/20 0.37
▸ KDM5B Q9UGL1 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ EGLN1 Q9GZT9 3/20 0.34
▸ HTT P42858 1/20 0.34
▸ PIK3R1 P27986 1/20 0.33
▸ ALKBH1 Q13686 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ PIK3CG P48736 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23386845 0.85 NPC1 (0.38) POLBMAPTRAB9ASMN1; SMN2HTT
SCHEMBL31352213 0.85 KDM4E (0.36) POLBKMOLMNASMN1; SMN2HSD17B10
SCHEMBL24158877 0.82 PIK3CA (0.38) POLBPIK3CAKMT2ARAB9AMEN1
SCHEMBL31352077 0.81 SMN1; SMN2 (0.48) PIK3CAKMT2ALMNARAB9ASMN1; SMN2
SCHEMBL24568627 0.79 HRH3 (0.41) POLBMAPTKMT2ALMNASMN1; SMN2
SCHEMBL21576558 0.77 SMN1; SMN2 (0.39) PIK3CAMAPTKMT2ALMNASMN1; SMN2
SCHEMBL24567562 0.77 MAPK1 (0.45) RAB9ASMN1; SMN2HTT
SCHEMBL24568379 0.76 CNR1 (0.37) POLBMAPTKMT2ASMN1; SMN2MEN1
SCHEMBL21570231 0.74 ALDH1A1 (0.37) POLBMAPTKMT2ASMN1; SMN2HSD17B10
SCHEMBL1393022 0.71 ALDH1A1 (0.39) POLBMAPTKMT2ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 — — EP disclosed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 — — EP disclosed
US-20250197421-A1 MCL1 INHIBITORS GILEAD SCIENCES, INC. 2025-06-19 — — US disclosed
US-12202842-B2 MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2025-01-21 — — US disclosed
WO-2025002177-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2025-01-02 — — WO disclosed
CN-114867530-B MCL1 inhibitors 吉利德科学公司 2024-08-16 — — CN disclosed
CN-117304130-A MCL-1 inhibitors 吉利德科学公司 2023-12-29 — — CN disclosed
US-20230348494-A1 MCL1 INHIBITORS GILEAD SCIENCES, INC. 2023-11-02 — — US disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
US-10988451-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2021-04-27 — — US disclosed
US-10988451-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2021-04-27 — — US disclosed
EP-3793565-A1 MCL-1 INHIBITORS Gilead Sciences, Inc. (US) 2021-03-24 — — EP disclosed
CN-112118845-A MCL-1 inhibitors 吉利德科学公司 2020-12-22 — — CN disclosed
US-20200331870-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2020-10-22 — — US disclosed
US-20200331870-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2020-10-22 — — US disclosed
US-10703733-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-07 — — US disclosed
US-10703733-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-07 — — US disclosed
US-20190352271-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2019-11-21 — — US disclosed
US-20190352271-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2019-11-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352271-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 POLB 1069/4885KMO 4601/4885PIK3CA 991/4885
US-20200331870-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 POLB 1069/4885KMO 4601/4885PIK3CA 991/4885
US-20230312490-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 POLB 1069/4885KMO 4601/4885PIK3CA 991/4885
US-10703733-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 POLB 1069/4885KMO 4601/4885PIK3CA 991/4885
US-12202842-B2 MCL1 inhibitors MCL1, BCL2L1, BCLAF1 POLB 1427/4885KMO 4618/4885PIK3CA 1121/4885
US-20230348494-A1 MCL1 INHIBITORS MCL1, BCL2L1, BCLAF1 POLB 1287/4885KMO 4636/4885PIK3CA 1056/4885
US-20250197421-A1 MCL1 INHIBITORS MCL1, BCL2L1, BCLAF1 POLB 1287/4885KMO 4636/4885PIK3CA 1056/4885
US-10988451-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 POLB 1069/4885KMO 4601/4885PIK3CA 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.